Anybody follow this one ?

Review of the six months ended 31st October 2003

Outlook

Much has been achieved in the recent past leading to a positive perspective of
the future. FDA approval of the portable scanner and the possibility of entering
the US market, the setting up of an international distribution network and
improvements to the UK selling organisation, together with the enhancements to
the existing product range, are all significant and reassuring achievements
pointing to higher sales levels in the future. In addition, the progress made in
Mediwatch Biomedical Limited provides confidence in the long term prospects for
the Group.

Full review

http://www.uk-wire.com/cgi-bin/articles/200401280700167076U.html

RNS Number:7607U
Mediwatch PLC
29 January 2004


Mediwatch plc ('Mediwatch' or 'the Company')

Directors' Shareholdings


Rugby, UK. 29 January 2004 ... The Company received notification today that
Philip Stimpson, Chief Executive Officer of the Company, bought 125,000
ordinary shares in the Company at a price of 8.03 pence each on 28 January 2004.
Mr Stimpson now has a beneficial interest in 15,125,000 shares in the Company
representing 18.44 per cent of the issued share capital of that class.

The Company received notification today that Kevin Middis, Finance Director,
bought 60,000 ordinary shares in the Company at a price of 8.03 pence each on 28
January 2004.

The Company received notification today that Omer Karim, Non-Executive Medical
Research Director, bought 475,000 ordinary shares in the Company at a price of
8.03 pence each on 28 January 2004. Mr Karim now has a beneficial interest in
3,033,600 shares in the Company representing 3.70 per cent of the issued share
capital of that class.

Ends




For more information, visit the company's website www.mediwatch.com or contact:



Yvonne Alexander De Facto +44 20 7496 3316
y.alexander@defacto.com



Philip Stimpson Mediwatch +44 788 547 888
philip.stimpson@mediwatch.com





Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.




This information is provided by RNS
The company news service from the London Stock Exchange
END

Price 9.0-9.5 pence, rising nicely, up 17.4%.

Could be worth adding more at these prices. The distribution deal should be imminent.

In addition, good volume so far today. Trades over 15,000 shares are delayed by an hour. So the majority of earlier larger buys have appeared in the sell column.

is it still worth to buy it now? any furhter new will be announce?

A distribution deal is due sometime soon. Price seems to have found a new trading range at the moment with limited downside.

so when will be good to buy?

Mediwatch mentioned in Shares Magazine this week.

Mediwatch chiefs scan for US profits
The likely prospect of a lucrative US distribution deal is good news for investors in AIM-listed Mediwatch (MDW).

Following publication of the interims, chief executive Philip Stimpson bought 125,000 shares and finance director Kevin Middis acquired 60,000 shares at 8.03p.

The company produces a bladder scanner which has recently received marketing approval from the FDA. This diagnostic kit can be used by a trained person, who need not be a doctor, to discover whether a patient needs specialist secondary care. It will be used in primary healthcare to screen for prostate illnesses.

Currently, the group has distribution agreements with CR Bard, one of the worlds largest suppliers of urological equipment, for distribution in parts of Europe. It is hoping to extend these arrangements to include Canada, Germany, Italy and Spain. It has signed similar distribution arrangements with a GE subsidiary to cover Japan and South-East Asia and is in the final stages of discussions about a distribution arrangement in the US an announcement is, we believe, imminent. Although currently most of the groups sales are in the UK, the company believes that in 2004/05, most will be generated overseas.

Last year, the company had to place 10 million shares at 2.5p and then seven million at 3.4p. Now that it has received FDA approval, the markets enthusiasm should continue to grow, especially when it is able to name its US partner. In the medium term, it is possible that its technology will attract a predator.

added at the very end of the day, thats around 35% up in 2 days. Far more to come me thinks.

cheers GF.

This was taken from another board, if true then very interesting.

Institute report - This company (MDW) is involved with a study that will inform future policy on screening for prostate cancer into a national programme. The study will take many years BUT results as they appear will be acted on earlier than the completed study. The bladder is the most likely area to develop cancer caused by radiation from X-rays ( The Lancet 2004) and ways to aviod this by new types of machinary is crucial. Any new ways to manage men with screen - detection of this disease will be supported by large sums of money.

up by 7% today ..how far can this go ..holding tight

Dont think we have seen anything until the distribution deal is announced.

cheers GF.

Up again guys thats over 40% in three days. Still more to come though a lot more.

cheers GF.

Fingers crossed hope to be hearing about this distribution deal soon.

cheers GF.

OK - I'm in as of tomorrow for a few.

An interesting post from elsewhere a couple of days ago helps to put the fundamentals into perspective, during this frantic climb:

"Estimated annual turnover in US alone of $20m. Plus signing new distrubution deals for new products to other countries - news that will be coming in the same RNS. So add 50% for other turnover worldwide and thats $30m turnover. Say thats approx 17m (sterling) turnover potential for 04/05. Mkt cap of growth companies typically three times sales (its a far better guide than PE ratios for this sort of high growth stock). So that three times sales = fair value mkt cap of 3 x 17m = 51m mkt cap is fair value. Its now at a tiddly mkt cap of 10m ish !!! Multiple from here of 5 times the share price = genuine fair value mkt cap.

Plus : The bladder scanner is getting distrubuted worldwide in the same RNS so my annual turnover estimate of $30m only adds in $10m from outside the US, which is very conservative."

Overgrowth - I read that post too and posted it on GF's thread - do you know enough about MDW and enough about calculating the sums in this to know if the above is accurate or just one person's very optimistic view?

Very strong looking TA.


Positive Candidate (Medium term) - Feb 11, 2004
Has risen 555% since the bottom on 5 Jan 2004 at 2.25. An approximate horizontal trend is broken up. A continued strong development is indicated, and the stock now meets support on possible reactions down towards the trend lines. RSI is overbought. The stock can still rise further, and we should see a decreasing RSI before this is used as a negative signal. Positive volume balance, i.e. high volume in days of rising prices and low volume in days of falling prices, strengthens the stock in the short term. The stock has support at p 3.50. High risk with an average difference between the lowest and the highest price of the month of 46%.


cheers Gf.

it seemed more seller rather than buyer now. can you confirmed.

No problems I added again on the weakness this afternoon, and see these making me a very decent return.

cheers Gf.